GeoVax Labs Inc (GOVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeoVax Labs Inc (GOVX) has a cash flow conversion efficiency ratio of -1.266x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.21 Million) by net assets ($4.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GeoVax Labs Inc market cap and net worth for the company's overall valuation and market capitalisation.
GeoVax Labs Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how GeoVax Labs Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GeoVax Labs Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeoVax Labs Inc ranked by their cash flow conversion efficiency. Explore GeoVax Labs Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spectra Systems Corp
LSE:SPSY
|
0.210x |
|
Acutus Medical Inc
NASDAQ:AFIB
|
0.350x |
|
4BASEBIO UK SOCIETAS
LSE:4BB
|
-0.703x |
|
Jubilee Platinum
LSE:JLP
|
0.028x |
|
Braemar Plc
LSE:BMS
|
0.012x |
|
Urbanimmersive Inc
V:UI
|
-0.002x |
|
Meridian Bhd
KLSE:5040
|
-0.045x |
|
NeutriSci International Inc
V:NU
|
0.006x |
Annual Cash Flow Conversion Efficiency for GeoVax Labs Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of GeoVax Labs Inc from 1996 to 2024. View GeoVax Labs Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.05 Million | $-24.68 Million | -4.888x | -11.90% |
| 2023-12-31 | $5.76 Million | $-25.17 Million | -4.368x | -510.53% |
| 2022-12-31 | $26.60 Million | $-19.03 Million | -0.715x | +72.13% |
| 2021-12-31 | $4.36 Million | $-11.20 Million | -2.567x | -792.97% |
| 2020-12-31 | $9.57 Million | $-2.75 Million | -0.287x | -132.36% |
| 2019-12-31 | $-1.57 Million | $-1.40 Million | 0.888x | -41.17% |
| 2018-12-31 | $-1.02 Million | $-1.54 Million | 1.510x | -71.29% |
| 2017-12-31 | $-321.06K | $-1.69 Million | 5.259x | +164.96% |
| 2016-12-31 | $240.37K | $-1.95 Million | -8.096x | -260.52% |
| 2015-12-31 | $1.20 Million | $-2.71 Million | -2.246x | -14.40% |
| 2014-12-31 | $1.15 Million | $-2.25 Million | -1.963x | -192.77% |
| 2013-12-31 | $2.53 Million | $-1.69 Million | -0.671x | +68.39% |
| 2012-12-31 | $1.15 Million | $-2.44 Million | -2.121x | -391.54% |
| 2011-12-31 | $703.61K | $-303.62K | -0.432x | +60.52% |
| 2010-12-31 | $1.84 Million | $-2.01 Million | -1.093x | -187.18% |
| 2009-12-31 | $3.74 Million | $-1.43 Million | -0.381x | +56.44% |
| 2008-12-31 | $2.71 Million | $-2.37 Million | -0.874x | +29.15% |
| 2007-12-31 | $2.65 Million | $-3.27 Million | -1.233x | -104.63% |
| 2006-12-31 | $2.20 Million | $-1.33 Million | -0.603x | -341.49% |
| 2005-12-31 | $-5.72 Million | $-1.43 Million | 0.250x | -0.01% |
| 2004-12-31 | $-4.95 Million | $-1.23 Million | 0.250x | +430.50% |
| 2003-12-31 | $-3.82 Million | $288.31K | -0.076x | +96.33% |
| 2001-12-31 | $2.05 Million | $-4.21 Million | -2.056x | -241.90% |
| 2000-12-31 | $10.52 Million | $-6.33 Million | -0.601x | +92.55% |
| 1999-12-31 | $552.34K | $-4.46 Million | -8.070x | -335.13% |
| 1998-12-31 | $2.89 Million | $-5.35 Million | -1.855x | -330.19% |
| 1997-12-31 | $5.68 Million | $-2.45 Million | -0.431x | -14.43% |
| 1996-12-31 | $3.09 Million | $-1.17 Million | -0.377x | -- |
About GeoVax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marb… Read more